BioXcel Therapeutics's change in inventory for the quarter that ended in Dec. 2024 was $0.85 Mil. It means BioXcel Therapeutics's inventory
declined by $0.85 Mil
from Sep. 2024 to Dec. 2024 .
BioXcel Therapeutics's change in inventory for the fiscal year that ended in Dec. 2024 was $1.31 Mil. It means BioXcel Therapeutics's inventory
declined by $1.31 Mil
from Dec. 2023 to Dec. 2024 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioXcel Therapeutics's Days Inventory for the quarter that ended in Dec. 2024 was 120.86.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioXcel Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.75.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioXcel Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 3.01.
BioXcel Therapeutics Change In Inventory Historical Data
The historical data trend for BioXcel Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (NAS:BTAI) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioXcel Therapeutics's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioXcel Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics Change In Inventory Related Terms
Thank you for viewing the detailed overview of BioXcel Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BTAI has been successfully added to your 